SLAMF7 and cancer: Therefore, the concerted role of SLAMF7 and SLAMF8 in orchestrating human pDC responses against bacteria suggests that cell-specific blockade of these receptors may constitute a promising therapy to abate pDC activation and hyperproduction of type I IFN during infection, as well as in autoimmune disorders and cancer.